Telli, T. Et Al. 2023. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.. The Prostate , vol.83 , 792-800.

Telli, T., Tuncel, M., Karabulut, E., Aksoy, S., Erman, M., Akdogan, B., ... Caglar, M.(2023). Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.. The Prostate , vol.83, 792-800.

Telli, Tugce Et Al. "Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.," The Prostate , vol.83, 792-800, 2023

Telli, Tugce Et Al. "Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.." The Prostate , vol.83, pp.792-800, 2023

Telli, T. Et Al. (2023) . "Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.." The Prostate , vol.83, pp.792-800.

@article{article, author={Tugce Telli Et Al. }, title={Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.}, journal={The Prostate}, year=2023, pages={792-800} }